Celldex Therapeutics, Inc. (CLDX) Operating cash flow 2016–2025
Celldex Therapeutics, Inc. (CLDX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$210.9MFY2025 · since FY2016: -$113.0M → -$210.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$210.9M | -33.7% |
| FY2024 | -$157.8M | -47.1% |
| FY2023 | -$107.3M | -3.4% |
| FY2022 | -$103.7M | -70.3% |
| FY2021 | -$60.9M | -50.7% |
| FY2020 | -$40.4M | +13.0% |
| FY2019 | -$46.4M | +38.3% |
| FY2018 | -$75.2M | +24.7% |
| FY2017 | -$99.9M | +11.6% |
| FY2016 | -$113.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CLDX financial trends
CLDX RevenueCLDX Net incomeCLDX Net marginCLDX Gross profitCLDX Gross marginCLDX Operating incomeCLDX Operating marginCLDX Free cash flowCLDX Capital expendituresCLDX Return on equityCLDX Stock buybacksCLDX Dividends paidCLDX Total assetsCLDX Total liabilitiesCLDX Shareholders’ equityCLDX overview →